Our top pick for
Vaccinex, Inc is a biotechnology business based in the US. Vaccinex shares (VCNX) are listed on the NASDAQ and all prices are listed in US Dollars. Vaccinex employs 45 staff and has a trailing 12-month revenue of around USD$625,000.
|Latest market close||USD$2.3|
|52-week range||USD$1.63 - USD$9.6|
|50-day moving average||USD$1.9529|
|200-day moving average||USD$3.8249|
|Wall St. target price||USD$13.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.011|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-05)||7.98%|
|1 month (2020-12-12)||N/A|
|3 months (2020-10-12)||10.05%|
|6 months (2020-07-12)||N/A|
|1 year (2020-01-12)||N/A|
|2 years (2019-01-12)||N/A|
|3 years (2018-01-12)||N/A|
|5 years (2016-01-12)||N/A|
|Gross profit TTM||USD$324,000|
|Return on assets TTM||-120.96%|
|Return on equity TTM||-748.42%|
|Market capitalisation||USD$46.6 million|
TTM: trailing 12 months
There are currently 553,693 Vaccinex shares held short by investors – that's known as Vaccinex's "short interest". This figure is 31.3% down from 805,500 last month.
There are a few different ways that this level of interest in shorting Vaccinex shares can be evaluated.
Vaccinex's "short interest ratio" (SIR) is the quantity of Vaccinex shares currently shorted divided by the average quantity of Vaccinex shares traded daily (recently around 1.1 million). Vaccinex's SIR currently stands at 0.52. In other words for every 100,000 Vaccinex shares traded daily on the market, roughly 520 shares are currently held short.
However Vaccinex's short interest can also be evaluated against the total number of Vaccinex shares, or, against the total number of tradable Vaccinex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaccinex's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Vaccinex shares in existence, roughly 20 shares are currently held short) or 0.0448% of the tradable shares (for every 100,000 tradable Vaccinex shares, roughly 45 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaccinex.
Find out more about how you can short Vaccinex stock.
We're not expecting Vaccinex to pay a dividend over the next 12 months.
Over the last 12 months, Vaccinex's shares have ranged in value from as little as $1.63 up to $9.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaccinex's is 1.8054. This would suggest that Vaccinex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.